Showing results (461-470 of 498) with videos related to

Sort By:
Pageof 50
Journal of Human Immunity|February 26, 2026
Human ISG15 deficiency unveils impaired healing of ulcerations via type I interferon-mediated fibrosisChristos Sazeides, Lorenzo Cuollo, Ikjot Sidhu, et al.
Cancer Research|May 29, 2000
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell linesG L Scheffer, M Maliepaard, A C Pijnenborg, et al.
Cancers|October 28, 2023
The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint InhibitorsIslam Eljilany, Payman Ghasemi Saghand, James Chen, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|February 2, 2010
Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertensionZhi-Cheng Jing, Geoff Strange, Xian-Yang Zhu, et al.
Cancer Cell|October 20, 2012
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomasXinwei Zhang, Xiaohong Zhao, Warren Fiskus, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|January 27, 2017
Molecular genetic findings and clinical correlations in 100 patients with Joubert syndrome and related disorders prospectively evaluated at a single centerThierry Vilboux, Daniel A Doherty, Ian A Glass, et al.
Plos Genetics|October 21, 2015
The Ciliopathy Protein CC2D2A Associates with NINL and Functions in RAB8-MICAL3-Regulated Vesicle TraffickingRuxandra Bachmann-Gagescu, Margo Dona, Lisette Hetterschijt, et al.
Oncogene|December 17, 2002
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cellsMei Huang, Jay F Dorsey, P K Epling-Burnette, et al.
American Journal of Human Genetics|August 9, 2014
Mutations in LAMA1 cause cerebellar dysplasia and cysts with and without retinal dystrophyKimberly A Aldinger, Stephen J Mosca, Martine Tétreault, et al.
British Journal of Cancer|October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumoursI Brana, R Berger, T Golan, et al.
Pageof 50